AbbVie’s biggest deal since 2019 could land soon
AbbVie (ABBV) is closing in on a deal to buy Apogee Therapeutics for $10.9 billion in cash, according to a Reuters report citing people familiar with the matter in the Financial Times. The price values Apogee at a roughly 60% premium to its closing share price on Thursday, June 18, a steep markup ...
The Source
THE STREET
Business
Trump bought these health care stocks in 2026; should you?
THE STREET·1h ago·3 min read
Business
Oil prices face sudden $150 spike after vital route shuts
THE STREET·1h ago·3 min read
Business
Morgan Stanley gives Google stock investors reason to rethink AI spending
THE STREET·54m ago·3 min read
Business
Bath & Body Works Ditches 90s Nostalgia in Gen Z Pivot
THE STREET·40m ago·3 min read
Related
On this beat
Business
Trump bought these health care stocks in 2026; should you?
THE STREET·1h ago·3 min read
Business
Oil prices face sudden $150 spike after vital route shuts
THE STREET·1h ago·3 min read
Business
Morgan Stanley gives Google stock investors reason to rethink AI spending
THE STREET·54m ago·3 min read
Business
Bath & Body Works Ditches 90s Nostalgia in Gen Z Pivot
THE STREET·40m ago·3 min read